Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients

References

• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• KimESHirshVMokTGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet200837296521809181819027483
   PubMed Web of Science ®Google Scholar
• JackmanDPaoWRielyGJClinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerJ Clin Oncol201028235736019949011
   PubMed Web of Science ®Google Scholar
• SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med201137575ra26
   PubMed Web of Science ®Google Scholar
• AsamiKOkumaTHirashimaTContinued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutationsLung Cancer201379327628223261231
   PubMedGoogle Scholar
• FaehlingMEckertRKampTEGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survivalLung Cancer201380330631223489557
   PubMed Web of Science ®Google Scholar
• YangJJChenHJYanHHClinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancerLung Cancer2013791333923079155
   PubMed Web of Science ®Google Scholar
• BeasleyMBBrambillaETravisWDThe 2004 World Health Organization classification of lung tumorsSemin Roentgenol2005402909715898407
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• ChmieleckiJFooJOxnardGROptimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingSci Transl Med201139090ra59
   PubMed Web of Science ®Google Scholar
• RielyGJKrisMGZhaoBProspective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimusClin Cancer Res200713175150515517785570
   PubMed Web of Science ®Google Scholar
• ChaftJEOxnardGRSimaCSKrisMGMillerVARielyGJDisease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial designClin Cancer Res201117196298630321856766
   PubMed Web of Science ®Google Scholar
• GoldbergSBOxnardGRDigumarthySChemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitorsOncologist201318111214122024072220
   PubMed Web of Science ®Google Scholar
• GiacconeGHerbstRSManegoldCGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1J Clin Oncol200422577778414990632
   PubMed Web of Science ®Google Scholar
• HerbstRSGiacconeGSchillerJHGefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2J Clin Oncol200422578579414990633
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRTRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol200523255892589916043829
   PubMed Web of Science ®Google Scholar
• GatzemeierUPluzanskaASzczesnaAPhase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation TrialJ Clin Oncol200725121545155217442998
   PubMed Web of Science ®Google Scholar
• SoriaJCWuYLNakagawaKGefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialLancet Oncol201516899099826159065
   PubMed Web of Science ®Google Scholar
• ParkKYuCJKimSWFirst-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION studyJAMA Oncol20162330531226720423
   PubMed Web of Science ®Google Scholar
• BalakMNGongYRielyGJNovel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitorsClin Cancer Res200612216494650117085664
   PubMed Web of Science ®Google Scholar
• CostaDBHalmosBKumarABIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutationsPLoS Med20074101669167917973572
   PubMed Web of Science ®Google Scholar
• BeanJRielyGJBalakMAcquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinomaClin Cancer Res200814227519752519010870
   PubMed Web of Science ®Google Scholar